TY - JOUR AU - Loureiro, Robyn M. AU - Dumin, Jo Ann AU - McKee, Timothy D. AU - Austin, Wesley F. AU - Fuller, Nathan O. AU - Hubbs, Jed L. AU - Shen, Ruichao AU - Jonker, Jeff AU - Ives, Jeff AU - Bronk, Brian S. AU - Tate, Barbara PY - 2013 DA - 2013/04/18 TI - Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models JO - Alzheimer's Research & Therapy SP - 19 VL - 5 IS - 2 AB - Modulation of the gamma-secretase enzyme, which reduces the production of the amyloidogenic Aβ42 peptide while sparing the production of other Aβ species, is a promising therapeutic approach for the treatment of Alzheimer's disease. Satori has identified a unique class of small molecule gamma-secretase modulators (GSMs) capable of decreasing Aβ42 levels in cellular and rodent model systems. The compound class exhibits potency in the nM range in vitro and is selective for lowering Aβ42 and Aβ38 while sparing Aβ40 and total Aβ levels. In vivo, a compound from the series, SPI-1865, demonstrates similar pharmacology in wild-type CD1 mice, Tg2576 mice and Sprague Dawley rats. SN - 1758-9193 UR - https://doi.org/10.1186/alzrt173 DO - 10.1186/alzrt173 ID - Loureiro2013 ER -